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Adipokines, Insulin Resistance,
and Coronary Artery Calcification
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Thomas Rhodes, MSPH,‡ Cynthia Girman, DRPH,‡ Muredach P. Reilly, MB*
Philadelphia and West Point, Pennsylvania; and Washington, DC
Objectives We evaluated the hypothesis that plasma levels of adiponectin and leptin are independently but oppositely asso-
ciated with coronary artery calcification (CAC), a measure of subclinical atherosclerosis. In addition, we assessed
which biomarkers of adiposity and insulin resistance are the strongest predictors of CAC beyond traditional risk
factors, metabolic syndrome, and plasma C-reactive protein (CRP).
Background Adipokines are fat-secreted biomolecules with pleiotropic actions that converge in diabetes and cardiovascular
disease.
Methods We examined the association of plasma adipocytokines with CAC in 860 asymptomatic, nondiabetic participants
in the SIRCA (Study of Inherited Risk of Coronary Atherosclerosis).
Results Plasma adiponectin and leptin levels had opposite and distinct associations with adiposity, insulin resistance,
and inflammation. Plasma leptin was positively (top vs. bottom quartile) associated with higher CAC after adjust-
ment for age, gender, traditional risk factors, and Framingham risk scores (tobit regression ratio 2.42 (95% con-
fidence interval [CI]: 1.48 to 3.95; p  0.002) and further adjustment for metabolic syndrome and CRP (tobit
regression ratio: 2.31; 95% CI: 1.36 to 3.94; p  0.002). In contrast, adiponectin levels were not associated with
CAC. Comparative analyses suggested that levels of leptin, interleukin-6, and soluble tumor necrosis factor
receptor-2, as well as the homeostasis model assessment of insulin resistance (HOMA-IR) index, predicted CAC
scores, but only leptin and HOMA-IR provided value beyond risk factors, metabolic syndrome, and CRP.
Conclusions In SIRCA, although both leptin and adiponectin levels were associated with metabolic and inflammatory mark-
ers, only leptin was a significant independent predictor of CAC. Of several metabolic markers, leptin and the
HOMA-IR index had the most robust, independent associations with CAC. (J Am Coll Cardiol 2008;52:231–6)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.016v
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odipokines are fat-secreted biomolecules with diverse sig-
aling effects that modulate insulin resistance, hepatic
ipoprotein production, and vascular inflammation (1). Two
n particular, adiponectin and leptin, are almost exclusively
at derived and have antithetic actions in insulin resistance
nd in vascular signaling (2). Because of these properties,
diponectin and leptin have been proposed as biomarkers of
dipose function that may add value in predicting cardio-
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ccepted April 28, 2008.ascular disease (CVD) risk and provide targets for thera-
eutic interventions.
Levels of adiponectin, an insulin-sensitizing hormone
ith anti-inflammatory properties (3), are reduced in obe-
ity, type 2 diabetes, and coronary artery disease (CAD)
ompared with controls (4–6). Indeed, several (7,8) but not
ll (9,10) epidemiologic studies suggest that reduced plasma
diponectin levels are independent predictors of CVD.
eptin, on the other hand, is a pleiotropic adipokine that
odulates innate immune functions and vascular signaling
n addition to its central role in regulation of appetite and
nergy expenditure (11). In contrast to adiponectin, leptin
evels directly correlate with insulin resistance, obesity
12,13), and several CVD risk factors (14). Leptin levels
ave been associated with CVD beyond body mass index
BMI) in some (15–17) but not all studies (18).
We previously examined the association of plasma levels
f C-reactive peptide (CRP), resistin, interleukin (IL)-6,
nd soluble tumor necrosis factor receptor-2 (sol-TNFR2),
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with coronary artery calcification
(CAC) in the SIRCA (Study of
Inherited Risk of Coronary Ath-
erosclerosis) (19–22). In this re-
port, we examined the associa-
tion of adiponectin and leptin
with CVD risk factors and CAC
in SIRCA and then compared
the relative value of all measured
biomarkers of adiposity and in-
sulin resistance in predicting
CAC scores beyond traditional
risk factors, metabolic syndrome,
and plasma CRP.
Methods
Study participants. SIRCA is a
single-center, community-based,
cross-sectional study of factors as-
sociated with CAC (21,23). Par-
ticipants were healthy adults 30
o 75 years with family histories of premature CVD but
ithout evidence of clinical CAD (defined as myocardial
nfarction, coronary revascularization, angiographic evi-
ence of CAD, or ischemia seen on a cardiac stress test),
iabetes, serum creatinine level 3.0 mg/dl, or elevated
otal cholesterol (300 mg/dl). This report focuses on 860
nrelated, nondiabetic SIRCA participants.
valuated parameters. Study subjects were evaluated in a
asting state at the General Clinical Research Center at the
ospital of the University of Pennsylvania, Philadelphia
21,23). Plasma levels of adiponectin, leptin, resistin, and
nsulin (Linco, St. Charles, Missouri), as well as IL-6 and
ol-TNFR2 (R&D Systems, Minneapolis, Minnesota),
ere measured by enzyme-linked immunosorbent assays.
he CRP levels were assayed as described (21). The
ntra-assay and interassay coefficients of variance for pooled
uman plasma were 5.7% and 9.9% for adiponectin; 5.5%
nd 12.4% for leptin; 4.6% and 4.3% for resistin; 4.1% and
1.6% for insulin; 8.7% and 10.9% for IL-6; 5.3% and
2.1% for sol-TNFR2; and 8.0% and 8.3% for CRP,
espectively. Framingham risk scores (FRS) were calculated
s described by Wilson et al. (24). Participants were classi-
ed as having metabolic syndrome using the National
holesterol Education Program (NCEP) definition (25).
he homeostasis model assessment of insulin resistance
HOMA-IR) index  fasting glucose (mmol/l)  fasting
nsulin (U/ml)/22.5 (26) was used as a measure of
nsulin resistance. Global Agatston CAC scores (27),
easured by electron beam tomography (Imatron, San
rancisco, California) were determined as previously
escribed (21,23).
tatistical analysis. Data are reported as median with
Abbreviations
and Acronyms
BMI  body mass index
CAC  coronary artery
calcium
CAD  coronary artery
disease
CRP  C-reactive protein
CVD  cardiovascular
disease
FRS  Framingham risk
score
HOMA-IR  homeostasis
model assessment of
insulin resistance
IL  interleukin
IMT  intima-media
thickness
LRT  likelihood-ratio test
sol-TNFR2  soluble tumor
necrosis factor receptor-2rst and third quartiles (Q1  25th percentile, Q3  75th hercentile) or mean  standard deviation for continuous
ariables and as proportions for categoric variables.
pearman correlations of plasma adiponectin and leptin
evels with other continuous variables are presented.
rude associations of adipokine levels with categoric
ariables were examined using the Kruskal-Wallis rank
est. Tobit regression, using natural log (CAC1) as the
utcome, was used for the analysis of CAC data because
f its marked right-skewed distribution and the presence
f many zero scores (28). The tobit model is designed to
ssess the relationship between explanatory variables and
censored dependent variable at one end, at which many
bservations are clustered. We chose this modeling be-
ause CAC scores are censored at zero and the use of
rdinary least-squares regression on such a nonnormal
istribution would produce biased estimates and invalid
nference. Tobit modeling has otherwise similar assump-
ions about error distributions as the linear regression
odel.
Because of potential gender differences in adipose asso-
iations with CVD, models are presented for each gender
eparately and combined when appropriate. The association
etween CAC and highest versus lowest quartile of adi-
onectin and leptin levels were assessed in incremental
odels including the variables age (age and age2), race,
ender, family history of CAD, exercise (none vs. any),
edications (aspirin, statins, angiotensin-converting en-
yme inhibitors), FRS, metabolic syndrome, and CRP.
ender differences in the association of adipokines with
AC were assessed using the likelihood-ratio test (LRT). A
riori BMI data were not included in the models because
dipokines may be intermediate in the causal pathway
etween adiposity and subclinical atherosclerosis.
We used the likelihood-ratio test in nested models to
ssess the incremental value of each biomarker of adipos-
ty and insulin resistance, adiponectin, leptin, resistin,
L-6, sol-TNFR2, HOMA-IR data (all included as
og-transformed variables), and metabolic syndrome in
redicting CAC scores beyond established risk factors.
tatistical analyses were performed using Stata 9.0 soft-
are (Stata Corporation, College Station, Texas). A tobit
egression model was fit in Stata (29) using the tobit
ommand with the ll(0) option to indicate left censoring
t a CAC score of 0.
esults
haracteristics of participants. As previously described
19,21), the SIRCA sample is predominantly Caucasian
Table 1). Plasma levels of adiponectin and leptin were
ignificantly higher in women than in men (p  0.001 for
oth). Almost 40% had CAC scores above the 70th per-
entile, consistent with accelerated atherosclerosis most
ikely related to recruitment strategy based on a family
istory of CVD.
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July 15, 2008:231–6 Adipokines and Coronary Calcificationifferential association of adiponectin and leptin with
ardiovascular risk factors. Adiponectin and leptin corre-
ated only modestly (and inversely) with each other, whereas
ssociations with lipid, metabolic, and inflammatory vari-
bles were greater for both adipokines in women than men
Online Appendix Table A). Among all factors, adiponec-
in’s strongest (direct) correlation was with plasma levels of
igh-density lipoprotein (HDL) cholesterol, whereas it was
nly modestly and inversely correlated with HOMA-IR,
diposity, and inflammatory markers. In contrast, leptin was
trongly associated with BMI, waist circumference, and
OMA, moderately correlated with inflammatory markers,
lood pressure, and apoB lipoproteins, but only weakly
nversely related to HDL cholesterol.
lasma levels of leptin, but not of adiponectin, are
ssociated with CAC. In simple models, adiponectin levels
ere not significantly correlated with CAC in either men or
omen, whereas leptin had a strong direct association with
AC across gender (Table 2). There were suggestive gender
ifferences in the association of adipokines with CAC in
ruder models, which were significant for adiponectin in
ge- and race-adjusted models (p  0.01). In fully adjusted
haracteristics of the SIRCA Study Sample
Table 1 Characteristics of the SIRCA Study Sample
Median (Q1–Q3)
Men (n  457) Women (n  403)
Age (yrs) 46 (40–51) 50 (44–57)
Total cholesterol (mg/dl) 199 (174–224) 211 (183–234)
LDL cholesterol (mg/dl) 126 (102–148) 125 (101–147)
HDL cholesterol (mg/dl) 42 (36–49) 58 (47–68)
Triglycerides (mg/dl) 126 (91–177) 112 (80–147)
10-yr CAD Framingham risk (%) 7 (4–8) 4 (2–6)
Smoking (%) 12.7 11.3
Blood pressure (mm Hg)
Systolic 128 (120–137) 125 (113–136)
Diastolic 79 (74–86) 75 (68–82)
Body mass index (kg/m2) 27.5 (25.2–30.3) 25.6 (22.8–30.2)
Waist circumference (cm) 95.3 (88.9–104.1) 81.3 (73.7–91.8)
Glucose (mg/dl) 95.1 (88–103) 91 (86–98)
Insulin (pmol/l) 44.7 (29.5–67.0) 37.9 (26.1–57.1)
HOMA-IR 1.5 (1.0–2.3) 1.3 (0.8–1.9)
Metabolic syndrome* (%) 28.8 22.1
C-reactive protein (mg/dl) 1.1 (0.5–2.1) 1.4 (0.6–3.7)
Adiponectin (g/ml) 13.1 (8.9–18.0) 21.4 (15.0–28.5)
Leptin (ng/ml) 5.5 (3.2–8.3) 15.9 (9.6–26.9)
Resistin (ng/ml) 5.2 (3.8–6.9) 5.9 (4.4–7.9)
IL-6 (pg/ml) 1.24 (0.80–1.9) 1.30 (0.84–2.12)
sol-TNF2 (ng/ml) 1.6 (1.4–1.9) 1.7 (1.4–2.0)
CAC
CAC mean score ( SD) 123 328 41 133
CAC median (IQR) 6 (1–70) 1 (0–13)
CAC 70% (%) 39.4 38.0
Metabolic syndrome as defined by the National Cholesterol Education Program; definition based
n fasting glucose cut point of 110 mg/dl.
CAC  coronary artery calcification; CAD  coronary artery disease; HDL  high-density
ipoprotein; HOMA-IR homeostasis model assessment of insulin resistance; IL interleukin; IQR
interquartile range; LDL  low-density lipoprotein; SIRCA  Study of Inherited Risk of Coronary
therosclerosis; sol-TNF2  soluble tumor necrosis factor receptor-2.odels, even after controlling for FRS, metabolic syn- hrome, and plasma CRP levels, the top quartile of leptin but
ot adiponectin was significantly associated with CAC
cores (Table 2).
omparison among adipocytokines, HOMA-IR, meta-
olic syndrome, and CRP in prediction of CAC scores.
n SIRCA, there was no evidence for major gender differ-
nces in the association of metabolic syndrome, HOMA-
R, IL-6, sol-TNFR2, and resistin with CAC in adjusted
nalyses (e.g., p  0.10, 0.37, 0.68, and 0.18, respectively,
or gender differences in age- and race-adjusted models).
herefore, except for adiponectin, results of these analyses
re presented for both genders combined. The HOMA-IR
ndex and plasma levels of leptin, IL-6, and sol-TNFR2, as
ell as the NCEP-defined metabolic syndrome (glucose cut
oint 110 mg/dl), provided significant improvements in
he association with CAC beyond traditional risk factors
nd FRS (Table 3). After further adjustment for metabolic
yndrome and CRP data, only HOMA-IR (LRT chi-
quare  10.39, p  0.01) and plasma leptin levels (LRT
hi-square  6.87, p  0.01) significantly improved model
rediction of CAC (Table 3).
iscussion
diponectin and leptin are fat-secreted hormones with
pposing actions on insulin resistance and vascular inflam-
ation. Plasma leptin and adiponectin had opposite corre-
ations with lipid, metabolic, and inflammatory risk factors,
ut we found that only plasma leptin levels were indepen-
ently associated with CAC. Further, in a comparison of
everal metabolic biomarkers, leptin and the HOMA-IR
ndex had the most robust associations with CAC scores
eyond traditional risk factors, NCEP-defined metabolic
yndrome, and plasma levels of CRP.
Leptin is an important negative regulator of body weight
11). Paradoxically, obesity is associated with increased
lasma leptin levels, most likely because of resistance to its
ctions in the setting of increased production by adipose
issue (30). Leptin activates the endothelium and induces
mooth muscle cell proliferation, and its receptors are
xpressed in atherosclerotic plaques (31). Recent studies
uggest an association between plasma leptin levels and
therosclerotic CVD in humans, including angiographic
AD (32) and CVD events (33). In a case- (n  377)
ontrol (n  783) study nested within the WOSCOPS
West of Scotland Coronary Prevention Study), plasma
eptin levels predicted CVD even after adjustments for
raditional risk factors, BMI, and plasma CRP levels (15).
owever, in a nested case-control study from the Quebec
ardiovascular Study Cohort, plasma leptin levels were not
elated to CVD events (18).
Few data are available on the association between leptin
nd direct measures of atherosclerosis in humans. Van den
eld et al. (34) found no association between plasma leptin
evels and carotid intima-media thickness (IMT) in 403
ealthy elderly men, whereas Ciccone et al. (35) reported an
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Adipokines and Coronary Calcification July 15, 2008:231–6ssociation of leptin with IMT in 126 healthy Italians. We
reviously reported that leptin levels were associated with
AC in a type 2 diabetic sample even after controlling for
stablished risk factors, including CRP and measures of
ubclinical vascular disease (16). Recently Iribarren et al.
36) reported an association of plasma leptin levels with
AC in older women in the ADVANCE (Atherosclerotic
isease, Vascular Function and Genetic Epidemiology)
tudy, but this association was not significant after control-
ing for metabolic risk factors and BMI data. In SIRCA, we
ound an association of plasma leptin with CAC even after
ontrolling for metabolic syndrome and CRP.
Adiponectin has emerged as a unique fat-secreted hor-
one that regulates insulin sensitivity (37). Atheroprotec-
ive effects may be directed through inhibition of the nuclear
actor kappa-B inflammatory pathway in vascular cells (38)
nd by attenuation of foam cell formation (39). Plasma
ssociation of Plasma Levels of Adiponectin and Leptin With Coron
Table 2 Association of Plasma Levels of Adiponectin and Lepti
Variables Adjusted for
Adiponectin
Basic model (i.e., age, gender, race)
Basic model, family history, exercise, medications, FRS
Basic model, family history, exercise, medications, metabolic syndrome
Basic model, family history, exercise, medications, FRS, metabolic syndrome
Above model plus CRP
Leptin
Basic model (i.e., age, gender, race)
Basic model, family history, exercise, medications, FRS
Basic model, family history, exercise, medications, metabolic syndrome
Basic model, family history, exercise, medications, FRS, metabolic syndrome
Above model plus CRP
esults of tobit regression are presented as the ratio of increase in coronary artery calcifica
ngiotensin-converting enzyme inhibitors. *p  0.01 for gender interaction.
CI  confidence interval; CRP  C-reactive protein; FRS  Framingham risk score.
ncremental Value of Metabolic Syndrome, CRP,dipocytokines, or HOMA-IR in Predicting Coronaryalcium Scor Beyond Establish Risk Fact rs
Table 3
Incremental Value of Metabolic Syndrome, CRP,
Adipocytokines, or HOMA-IR in Predicting Coronary
Calcium Scores Beyond Established Risk Factors
Likelihood Ratio Test (Chi-Square)
Variable Added
to Model
Added to
Full Model*
Added to Full Model With CRP
and Metabolic Syndrome
Metabolic syndrome 6.78† —
CRP 2.05 —
Adiponectin 0.52 —
Adiponectin in men 3.56 —
Adiponectin in women 0.24 —
Resistin 1.69 —
Leptin 11.4‡ 6.87†
HOMA-IR 14.83‡ 10.39‡
IL-6 7.31† 2.92
sol-TNFR2 4.73§ 2.19
obit regression model of coronary artery calcification data. All continuous variables were included
n the model as log-transformed variables. Likelihood-ratio test chi-square statistics and p values
re reported for comparison of nested models when each metabolic variable was added to a full
odel containing established risk factors. *Full model includes age, gender, race, 10-year FRS,
amily history, exercise, and medications (aspirin, statin, angiotensin-converting enzyme inhibitor).o
p  0.01. ‡p  0.001. §p  0.05.
Abbreviations as in Tables 1 and 2.evels are depressed in patients with CAD (40) and are
ssociated with clinical CVD in patients with diabetes (7).
nested case-control study by Maahs et al. (41) suggested
hat low levels of plasma adiponectin predict short-term
AC progression, more so in nondiabetics. Several recent
rospective studies of clinical CVD, however, have been
egative. In a nested case-control study from the Strong
eart Study, there was no association with incident CAD
vents (10). Similarly, in the British Women’s Heart and
ealth Cohort Study, adiponectin levels were not associated
ith CVD (9). More recently, Sattar et al. (42) looked at
89 men with fatal and nonfatal CAD and 1,231 controls
nd found no difference in median adiponectin levels
espite adiponectin associations with HDL and CRP. A
-study meta-analysis by the same authors failed to
emonstrate a consistent relationship of adiponectin with
AD events (42).
Despite correlations with lipids, metabolic factors, and
nsulin resistance, we also did not find an inverse association
f adiponectin levels with CAC. The reasons for conflicting
tudy findings are uncertain but may reflect differences in
tudy design and populations as well as heterogeneous
utcomes including subclinical atherosclerotic and different
VD outcomes. In fact, Steffes et al. (43) unexpectedly
ound a positive association of adiponectin with CAC in a
tudy of more than 3,000 young adults age 33 to 45 years.
inally, several studies suggest that the high molecular
eight adiponectin complex, but not the lower molecular
eight hexamer, may be the active signaling molecule
44,45). Few epidemiologic studies, however, have assayed
he different circulating forms of adiponectin.
We also determined which of several metabolic biomar-
ers predicted CAC scores beyond established clinical CVD
isk factors. Leptin, HOMA-IR, and to a lesser extent IL-6
nd sol-TNFR2, provided incremental value beyond FRS,
etabolic syndrome, and CRP. Our finding that
OMA-IR levels are associated with CAC beyond all
rtery Calcification in Tobit Multivariable Models
h Coronary Artery Calcification in Tobit Multivariable Models
men Ratio (95% CI) Men Ratio (95% CI) Combined Ratio (95% CI)
.60 (0.26–1.39) 1.36 (0.75–2.48) *
.22 (0.54–2.78) 1.44 (0.79–2.62) 1.28 (0.79–2.07)
.13 (0.48–2.69) 1.50 (0.82–2.75) 1.31 (0.80–2.14)
.36 (0.58–3.19) 1.55 (0.85–2.84) 1.40 (0.86–2.29)
.82 (0.76–4.34) 1.51 (0.82–2.76) 1.47 (0.89–2.41)
.64 (2.37–13.40) 3.26 (1.81–5.87) 3.77 (2.31–6.14)
.15 (1.36–7.31) 2.21 (1.20–4.08) 2.42 (1.48–3.95)
.45 (1.42–8.34) 2.25 (1.22–4.16) 2.54 (1.54–4.20)
.06 (1.28–7.30) 2.11 (1.13–3.91) 2.30 (1.39–3.80)
.99 (0.79–4.99) 2.68 (1.40–5.15) 2.31 (1.36–3.94)
ore for top versus bottom quartile of adipokine data. Medications included aspirin, statins,ary A
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July 15, 2008:231–6 Adipokines and Coronary Calcification46) studies that found that hyperinsulinemia and insulin
esistance indices were independently associated with ath-
rosclerosis and CVD. The clinical application of insulin-
ased measures, however, is challenging given the lack of
ssay standardization and because of ultradian and circadian
ariation in circulating insulin.
tudy limitations. This study has several limitations. The
tudy sample is cross-sectional, and causal relationships
annot be determined from the results. Moreover, it is a
tudy of a population consisting primarily of Caucasians
ith a family history of premature CVD who are otherwise
eemed to be at low risk; therefore, the generalizability of
ur findings across other populations and ethnic groups is
ncertain. In addition, CAC is not a direct measure of
oronary atherosclerosis. In autopsy studies, however, CAC
as been shown to be a quantitative estimate of coronary
therosclerosis (47). It has also been shown to be an
ndependent predictor of CVD (48).
onclusions
e found that plasma levels of leptin but not adiponectin
ere associated with CAC after controlling for traditional
ardiovascular risk factors, metabolic syndrome, and CRP
evels. Whether leptin signaling promotes human athero-
clerotic CVD directly remains to be established. Finally,
eptin levels and the HOMA-IR index had stronger asso-
iations with CAC scores than other adipocytokines in this
symptomatic sample. A systematic comparison of multiple
dipocytokine and insulin resistance biomarkers across di-
erse clinical settings is warranted to establish which provide
tility as metabolic biomarkers of clinical CVD.
eprint requests and correspondence: Dr. Muredach P. Reilly,
ardiovascular Institute, University of Pennsylvania Medical Cen-
er, 909 BRB 2/3, 421 Curie Boulevard, Philadelphia, Pennsylva-
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